全文获取类型
收费全文 | 62064篇 |
免费 | 5612篇 |
国内免费 | 2159篇 |
专业分类
耳鼻咽喉 | 670篇 |
儿科学 | 988篇 |
妇产科学 | 728篇 |
基础医学 | 12444篇 |
口腔科学 | 1022篇 |
临床医学 | 3932篇 |
内科学 | 9412篇 |
皮肤病学 | 1336篇 |
神经病学 | 4891篇 |
特种医学 | 1013篇 |
外国民族医学 | 16篇 |
外科学 | 4715篇 |
综合类 | 7339篇 |
现状与发展 | 10篇 |
预防医学 | 2476篇 |
眼科学 | 699篇 |
药学 | 9975篇 |
2篇 | |
中国医学 | 2659篇 |
肿瘤学 | 5508篇 |
出版年
2024年 | 57篇 |
2023年 | 1158篇 |
2022年 | 1481篇 |
2021年 | 2302篇 |
2020年 | 2036篇 |
2019年 | 2412篇 |
2018年 | 2484篇 |
2017年 | 2441篇 |
2016年 | 2143篇 |
2015年 | 2492篇 |
2014年 | 3585篇 |
2013年 | 4243篇 |
2012年 | 3666篇 |
2011年 | 4386篇 |
2010年 | 3505篇 |
2009年 | 3485篇 |
2008年 | 3274篇 |
2007年 | 3021篇 |
2006年 | 2695篇 |
2005年 | 2231篇 |
2004年 | 2107篇 |
2003年 | 1790篇 |
2002年 | 1399篇 |
2001年 | 1134篇 |
2000年 | 1045篇 |
1999年 | 844篇 |
1998年 | 730篇 |
1997年 | 725篇 |
1996年 | 606篇 |
1995年 | 717篇 |
1994年 | 600篇 |
1993年 | 496篇 |
1992年 | 419篇 |
1991年 | 383篇 |
1990年 | 332篇 |
1989年 | 277篇 |
1988年 | 206篇 |
1987年 | 204篇 |
1986年 | 206篇 |
1985年 | 369篇 |
1984年 | 424篇 |
1983年 | 250篇 |
1982年 | 291篇 |
1981年 | 238篇 |
1980年 | 206篇 |
1979年 | 163篇 |
1978年 | 119篇 |
1977年 | 112篇 |
1976年 | 128篇 |
1975年 | 87篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
《Research in social & administrative pharmacy》2022,18(9):3694-3698
In this paper, we argue that understanding and addressing the problem of poor-quality medical products requires a more interdisciplinary approach than has been evident to date. While prospective studies based on rigorous standardized methodologies are the gold standard for measuring the prevalence of poor-quality medical products and understanding their distribution nationally and internationally, they should be complemented by social science research to unpack the complex set of social, economic, and governance factors that underlie these patterns. In the following sections, we discuss specific examples of prospective quality surveys and of social science studies, highlighting the value of cross-sector partnerships in driving high-quality, policy-relevant research in this area. 相似文献
2.
3.
4.
胶质淋巴系统是一个主要由星形胶质细胞水通道蛋白4介导的依靠动脉、静脉周围血管间隙的脑脊液-脑组织液交换流动的系统,是阿尔茨海默病、脑卒中、帕金森病、失眠、抑郁症等脑病的共同特征,是一条新的脑代谢途径,可以清除包括β-淀粉样蛋白、乳酸在内的代谢产物。本文综合分析了全球有关胶质淋巴系统在脑部疾病的研究,得出:胶质淋巴系统可能为神经退行性疾病等发病机制和诊治策略研究带来新视角;胶质淋巴系统有望为一些脑部疾病诊断提供新的有效证据;胶质淋巴系统可能是脑部疾病治疗给药方式的新途径。 相似文献
5.
Lipid nanoparticles (LNPs) are becoming popular as a means of delivering therapeutics, including those based on nucleic acids and mRNA. The mRNA-based coronavirus disease 2019 vaccines are perfect examples to highlight the role played by drug delivery systems in advancing human health. The fundamentals of LNPs for the delivery of nucleic acid- and mRNA-based therapeutics, are well established. Thus, future research on LNPs will focus on addressing the following: expanding the scope of drug delivery to different constituents of the human body, expanding the number of diseases that can be targeted, and studying the change in the pharmacokinetics of LNPs under physiological and pathological conditions. This review article provides an overview of recent advances aimed at expanding the application of LNPs, focusing on the pharmacokinetics and advantages of LNPs. In addition, analytical techniques, library construction and screening, rational design, active targeting, and applicability to gene editing therapy have also been discussed. 相似文献
6.
7.
《Digestive and liver disease》2022,54(11):1486-1493
BackgroundCold snare polypectomy (CSP) is a promising technique for the removal of sessile serrated polyps (SSPs) ≥ 10 mm. However, the efficacy and safety of this technique remain undetermined.AimsWe aimed to comprehensively evaluate the efficacy and safety of CSP for SSPs ≥ 10 mm.MethodsPubMed, EMBASE, Web of Science and Cochrane Library were searched up to January 2021.ResultsA total of 10 studies consisting of 1727 SSPs (range, 10–40 mm) from 1021 patients were included. The overall rates of technical success, adverse events (AEs) and residual SSPs were 100%, 0.7% and 2.9%, respectively. Subgroup analysis showed that the rates of technical success and AEs were comparable between CSP and cold endoscopic mucosal resection (EMR) (99.9% vs. 100% and 1.3% vs. 0.5%, respectively), between the proximal and distal colon (100% vs. 99.9% and 0.3% vs. 0, respectively), and between polyps of 10–19 mm and ≥20 mm (99.8% vs. 100% and 0.9% vs. 0, respectively). However, subgroup analysis showed that the rate of residual SSPs was slightly lower in CSP compared with cold EMR (1.3% vs. 3.9%), as well as in polyps of 10–19 mm compared with those ≥20 mm (3.1% vs. 4.7%).ConclusionCSP was an effective and safe technique for removing SSPs ≥ 10 mm. 相似文献
8.
《Vaccine》2022,40(32):4296-4300
Advanced computational methodologies suggested SARS-CoV-2, nonstructural proteins ORF1AB, ORF3a, as the source of immunodominant peptides for T cell presentation. T cell immunity is long-lasting and compatible with COVID-19 pathology. Based on the supporting clinical data, nonstructural SARS-CoV-2 protein vaccines could provide global immunity against COVID-19. 相似文献
9.
10.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献